Institute of Cancer Research UK has described lysyl oxidase homolog 2 (LOXL2) inhibitors reported to be useful for the treatment of cancer and fibrosis.
Dana-Farber Cancer Institute Inc. has identified proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase ligand binding moiety covalently linked to an histone deacetylase 6 (HDAC6)/8 (HDAC8)-targeting moiety through a linker.
Zentaur Therapeutics USA Inc. has disclosed ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.
Transcode Therapeutics Inc. has entered into a co-research agreement with Debiopharm SA that will bring together Transcode’s proprietary TTX delivery platform with Debiopharm’s expertise in targeted drug delivery to co-develop targeted nucleic acid therapeutics for cancer.
Researchers from Shanghai Xianhui Pharmaceutical Co. Ltd. have detailed the discovery and preclinical characterization of novel photosensitizers as candidates for photodynamic therapy (PDT) and photodiagnosis in cancer.
It has been previously demonstrated that genetic variability of thioredoxin reductase 1 (TXNRD1) is associated with aging and age-associated phenotypes. Researchers from MD Anderson Cancer Center have now conducted work to assess the role of TXNRD1 in regulating tissue aging.
Applying chimeric antigen receptor (CAR) T-cell therapy to T-cell malignancies presents important limitations due to immune suppression caused by T-cell depletion, in addition to CAR T self-killing and CAR T transfection of malignant cells.
Genialis Inc. and Debiopharm SA have entered into an agreement to define and discover biomarkers within the DNA damage repair (DDR) biology space to predict the clinical benefit of one or more drugs in Debiopharm’s pipeline.
Domain Therapeutics SA has been awarded a grant as part of the Hospital-University Research in Health (RHU) SPRINT consortium, which seeks to progress a precision medicine for cutaneous T-cell lymphoma (CTCL).
Researchers from Renmin Hospital of Wuhan University have published results from their work that aimed to assess the role of exonuclease 1 (EXO1) in the progression of prostate cancer (PCa). A series of bioinformatic analyses revealed that EXO1 expression was higher in PCa tissue compared to normal tissue, and that high EXO1 expression predicted poor prognosis in PCa patients.
RSS
